Buy StanChart, sell HSBC, says CLSA’s Tabbush
StanChart’s recent acquisitions and expansion sees it better placed than HSBC, which is managing exposure to toxic assets and sub-prime loans in the US and Europe, says CLSA’s head of Asian bank research Daniel Tabbush.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts